CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma

BRAF is a serine/threonine kinase that harbors activating mutations in ∼7% of human malignancies and ∼60% of melanomas. Despite initial clinical responses to BRAF inhibitors, patients frequently develop drug resistance. To identify candidate therapeutic targets for BRAF inhibitor resistant melanoma,...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ziyi, Wang, Binbin, Gu, Shengqing, Jiang, Peng, Sahu, Avinash, Chen, Chen-Hao, Han, Tong, Shi, Sailing, Wang, Xiaoqing, Traugh, Nicole, Liu, Hailing, Liu, Yin, Wu, Qiu, Brown, Myles, Xiao, Tengfei, Boland, Genevieve M., Shirley Liu, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393575/
https://www.ncbi.nlm.nih.gov/pubmed/32413516
http://dx.doi.org/10.1016/j.gpb.2020.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393575/
https://www.ncbi.nlm.nih.gov/pubmed/32413516
http://dx.doi.org/10.1016/j.gpb.2020.02.002

Ejemplares similares